跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT04090957
NCT04090957已完成3 期

A Randomized Double-blind Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study II)

Estetra1 个研究点 分布在 1 个国家目标入组 1,015 人开始时间: 2019年9月27日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Estetra
入组人数
1,015
试验地点
1
主要终点
Mean Change in Weekly Frequency of Moderate to Severe Vasomotor Symptoms (VMS) From Baseline to Week 4 and Week 12 -- (Efficacy Study Part)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

A two-part study designed to evaluate the effect of Estetrol (E4) 15 mg, 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) in the Efficacy Study Part and the safety of E4 20 mg in the Safety Study Part.

详细描述

This is a two-part study:

Arm 1, 2, and 3: randomized, double blind

- Efficacy Study Part: designed to evaluate the frequency and severity of vasomotor symptoms [VMS] in both hysterectomized and non hysterectomized postmenopausal participants after treatment with two doses of E4 (15 mg or 20 mg) or placebo for 12 consecutive weeks. Thereafter, treatment proceeded for a total duration of up to 53 weeks, to continue the evaluation of secondary efficacy (effect on hemostasis, lipid and glucose metabolism, bone turnover, health-related quality of life [HRQoL] and treatment satisfaction [TS]), safety and the effect on the endometrium. For endometrial protection, all non-hysterectomized subjects received 200 mg progesterone (P4) once daily for 14 consecutive days, after completion of the E4/placebo treatment.

Arm 4: open label

- Safety Study Part: designed to evaluate the general safety, secondary efficacy (lipid and glucose metabolism, HRQoL and TS) after treatment with E4 20 mg for up to 53 weeks in hysterectomized and non hysterectomized postmenopausal participants. For endometrial protection, all non-hysterectomized subjects received 200 mg progesterone (P4) once daily for 14 consecutive days, after completion of the E4 treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

There are 3 blinded arms in the Efficacy part and 1 open-labeled arm in the Safety part.

入排标准

年龄范围
40 Years 至 65 Years（Adult, Older Adult）
性别
Female
接受健康志愿者
是

入选标准

  • •Signed and dated written informed consent form and any required privacy authorization prior to the initiation of any trial procedure, after the nature of the trial has been explained according to local regulatory requirements;
  • •Females ≥ 40 up to ≤ 65 years of age at randomization/treatment allocation;
  • •For hysterectomized subjects: documented hysterectomy must have occurred at least 6 weeks prior to the start of screening. Hysterectomy can be total or subtotal (i.e., cervix was not removed).
  • •For non-hysterectomized subjects: uterus with bi-layer endometrial thickness ≤ 4 mm on transvaginal ultrasound (TVUS)
  • •For non-hysterectomized subjects: endometrial biopsy taken during screening that reveals no abnormal result, i.e., presence of hyperplasia (simple or complex, with or without atypia), presence of carcinoma, and presence of disordered proliferative endometrium findings. The screening biopsy should have sufficient endometrial tissue for diagnosis. Biopsies without tissue or with insufficient tissue may be repeated once;
  • •Seeking treatment for relief of VMS associated with menopause;
  • •For the Efficacy Study part: at least 7 moderate to severe bothersome VMS per day or at least 50 moderate to severe bothersome VMS per week in the last 7 consecutive days during the Screening period;
  • •For the Safety Study part: at least 1 moderate to severe VMS per week;
  • •Body mass index ≥ 18.0 kg/m² up to ≤ 38.0 kg/m²;
  • •A mammogram that shows no sign of significant disease performed during screening or within 9 months prior to the start of screening;
  • •Post-menopausal status defined as any of the following:
  • •For non-hysterectomized subjects:
  • •At least 12 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) >40 milli-International unit (mIU)/mL (value obtained after washout of estrogen/progestin containing drugs, see exclusion criteria 18 and 20);
  • •or at least 6 months of spontaneous amenorrhea with serum FSH >40 mIU /mL and E2 <20 pg/mL (value obtained after washout of estrogen/progestin containing drugs, see exclusion criteria 18 and 20);
  • •or at least 6 weeks postsurgical bilateral oophorectomy;
  • •For hysterectomized subjects:
  • •serum FSH >40 mIU/mL and E2 <20 pg/mL (values obtained after washout of estrogen/progestin containing drug, see exclusion criteria 18 and 20);
  • •or at least 6 weeks post-surgical bilateral oophorectomy;
  • •Good physical and mental health, in the judgement of the Investigator as based on medical history, physical and gynecological examination, and clinical assessments performed prior to Visit 1;
  • •Able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions;
  • •Able and willing to complete trial daily diaries and questionnaires.

排除标准

  • •History of malignancy, with the exception of basal cell or squamous cell carcinoma of the skin if diagnosed more than 1 year prior to the Screening visit;
  • •Any clinically significant findings found by the Investigator at the breast examination and/or on mammography suspicious of breast malignancy that would require additional clinical testing to rule out breast cancer (however, simple cysts confirmed by ultrasound are allowed);
  • •Papanicolaou (PAP) test with atypical squamous cells undetermined significance (ASC-US) or higher (low-grade squamous intraepithelial lesion [LSIL], atypical squamous cells- cannot exclude high-grade squamous intraepithelial lesion [HSIL] [ASC-H], HSIL dysplastic or malignant cells) in sub-totally hysterectomized and non-hysterectomized subjects. Note: ASC-US is allowed if a reflex human papilloma virus (HPV) testing is performed and is negative for high risk oncogene HPV subtypes 16 and 18;
  • •For non-hysterectomized subjects:
  • •History or presence of uterine cancer, endometrial hyperplasia, or disordered proliferative endometrium;
  • •Presence of endometrial polyp;
  • •Undiagnosed vaginal bleeding or undiagnosed abnormal uterine bleeding;
  • •Endometrial ablation;
  • •Any uterine/endometrial abnormality that in the judgment of the investigator contraindicates the use of estrogen and/or progestin therapy. This includes presence or history of adenomyosis or significant myoma;
  • •Systolic blood pressure (BP) higher than 130 mmHg, diastolic BP higher than 80 mmHg during screening;
  • •History of venous or arterial thromboembolic disease (e.g., superficial or deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, angina pectoris, etc.), or first-degree family history of venous thromboembolism (VTE);
  • •History of known acquired of congenital coagulopathy or abnormal coagulation factors, including known thrombophilia's;
  • •Laboratory values of fasting glucose above 125 mg/dL and/or glycated hemoglobin above 7%;
  • •Dyslipoproteinaemia (LDL >190 mg/dL and/or triglycerides >300 mg/dL);
  • •Subjects smoking >15 cigarettes per day;
  • •Presence or history of gallbladder disease, unless cholecystectomy has been performed;
  • •Systemic lupus erythematosus;
  • •Any malabsorption disorders including gastric bypass surgery;
  • •History of acute liver disease in the preceding 12 months before the start of screening or presence or history of chronic or severe liver disease [alanine transaminase (ALT) or aspartate transaminase (AST) >2 x upper limit of normal (ULN), bilirubin >1.5 ULN], or liver tumors;
  • •Chronic or current acute renal impairment (estimated glomerular filtration rate <60 ml/min);
  • •Diagnosis or treatment of major psychiatric disorder (e.g., schizophrenia, bipolar disorder, etc.) in the judgement of the Investigator;
  • •Use of estrogen/progestin containing drug(s) up to:
  • •1 week before screening start for vaginal non-systemic hormonal products (rings, creams, gels);
  • •4 weeks before screening start for vaginal or transdermal estrogen or estrogen/progestin products;
  • •8 weeks before screening start for oral estrogen and/or progestin products and/or selective estrogen receptor modulator therapy;
  • •8 weeks before screening start for intrauterine progestin therapy;
  • •3 months before screening start for progestin implants or estrogen alone injectable drug therapy;
  • •6 months before screening start for estrogen pellet therapy or progestin injectable drug therapy;
  • •Use of androgen/dehydroepiandrosterone (DHEA) containing drugs:
  • •8 weeks before screening start for oral, topical, vaginal or transdermal androgen;
  • •6 months before screening start for implantable or injectable androgen therapy;
  • •Use of phytoestrogens or black cohosh for treatment of VMS up to 2 weeks before the start of screening;
  • •For the women participating in the Efficacy Study part: use of prescription or over-the-counter products used for the treatment of VMS, e.g., anti-depressants: paroxetine, escitalopram, methyldopa, opioid and clonidine up to 4 weeks before the start of screening, and venlafaxine and desvenlafaxine up to 3 months before the start of screening , and not willing to stop these during their participation in the trial;
  • •Not willing to stop any hormonal products as described in exclusion criteria 18, 19 and 20 during their participation in the trial;
  • •Inadequately treated hyperthyroidism with abnormal thyroid stimulating hormone (TSH) and free T4 at screening. Subjects with low or high TSH are allowed if free T4 at screening is within normal range;
  • •History or presence of allergy/intolerance to the investigational product or drugs of this class or any component of it, or history of drug or other allergy that, in the opinion of the Investigator contraindicates subject participation;
  • •For non-hysterectomized subjects: history or presence of allergy to peanuts;
  • •History of alcohol or substance abuse (including marijuana, even if legally allowed) or dependence in the previous 12 months before the start of screening as determined by the Investigator, based on reported observations;
  • •Sponsor or contract research organization (CRO) employees or employees under the direct supervision of the Investigator and/or involved directly in the trial;
  • •Subjects with known or suspected history of a clinically significant systemic disease, unstable medical disorders, life-threatening disease or current malignancies that would pose a risk to the subject in the opinion of the Investigator;
  • •Participation in another investigational drug clinical trial within 1 month (30 days) or having received an investigational drug within the last month (30 days) before the start of screening;
  • •Is judged by the Investigator to be unsuitable for any reason.

研究组 & 干预措施

Estetrol 15 mg - Efficacy Study Part

Experimental

Estetrol (E4) 15 mg, administered orally once daily for up to 53 weeks.

干预措施: Estetrol oral tablet (Drug)

Estetrol 20 mg - Efficacy Study Part

Experimental

Estetrol (E4) 20 mg, administered orally once daily for up to 53 weeks.

干预措施: Estetrol oral tablet (Drug)

Placebo - Efficacy Study Part

Placebo Comparator

Placebo, administered orally once daily for up to 53 weeks.

干预措施: Placebo oral tablet (Drug)

Estetrol 20 mg - Safety Study Part

Experimental

Estetrol (E4) 20 mg, administered orally once daily for up to 53 weeks.

干预措施: Estetrol oral tablet (Drug)

结局指标

主要结局

Mean Change in Weekly Frequency of Moderate to Severe Vasomotor Symptoms (VMS) From Baseline to Week 4 and Week 12 -- (Efficacy Study Part)

时间窗: Week 0 (Baseline), Week 4, Week 12.

Weekly frequency of moderate to severe VMS at Baseline = total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization (Week 0). Weekly frequency of moderate to severe VMS at Week X = total number (sum) of all recorded moderate to severe VMS experienced during the week X.

Mean Change in Severity of Moderate to Severe Vasomotor Symptoms (VMS) From Baseline to Week 4 and Week 12 -- (Efficacy Study Part)

时间窗: Week 0 (Baseline), Week 4, Week 12.

Mean severity score of VMS at Baseline: arithmetic mean of daily severity score values of moderate and severe VMS during the last 7 days prior randomization (Week 0). Mean severity score of VMS at Week 4 or 12: arithmetic mean of daily severity score values of moderate and severe VMS during Week 4 or 12. Daily severity score of VMS at Baseline = \[(2 x number of moderate VMS) + (3 x number of severe VMS)\]/(total number of moderate + severe VMS)\], if at least one moderate to severe VMS was recorded during the day. If documented absence of moderate to severe VMS during the day, daily severity was set to zero. Daily severity score of VMS Post-Baseline = \[(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)\]/(total number of mild + moderate + severe VMS)\], if at least one mild to severe VMS was recorded during the day. If documented absence of VMS during the day, daily severity was set to zero. Severity score: mild=1, moderate=2, severe=3.

次要结局

  • Mean Change From Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 in the Weekly Frequency of Moderate to Severe Vasomotor Symptoms (VMS) -- (Efficacy Study Part)(Week 0 (Baseline), Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12.)
  • Mean Change in Severity of Moderate and Severe Vasomotor Symptoms (VMS) From Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 -- (Efficacy Study Part)(Week 0 (Baseline), Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12.)
  • Mean Change From Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 in the Weekly Frequency of Mild to Severe Vasomotor Symptoms (VMS) -- (Efficacy Study Part)(Week 0 (Baseline), Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12.)
  • Percentage of Subjects With ≥50% and ≥75% Reduction From Baseline in the Weekly Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 -- (Efficacy Study Part)(Week 0 (Baseline), Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12.)
  • Percentage of Subjects With a Clinically Important Difference (CID) Compared With Baseline in the Weekly Frequency of Moderate to Severe VMS -- Week 4 and Week 12 -- Clinical Global Impression (CGI) Questionnaire -- (Efficacy Study Part)(Week 4, Week 12.)
  • Total Cholesterol -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Total Cholesterol -- (Safety Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Cholesterol/High-density Lipoprotein (HDL) Ratio -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Cholesterol/High-density Lipoprotein (HDL) Ratio -- (Safety Study Part).(Day 1 (Baseline), Weeks 12 and 52.)
  • High-density Lipoprotein (HDL)-Cholesterol -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • High-density Lipoprotein (HDL)-Cholesterol -- (Safety Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Low-density Lipoprotein (LDL)-Cholesterol -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52)
  • Low-density Lipoprotein (LDL)-Cholesterol -- (Safety Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Lipoprotein(a) -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Lipoprotein(a) -- (Safety Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Triglycerides -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Triglycerides -- (Safety Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Hemoglobin A1c -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Hemoglobin A1c -- (Safety Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Fasting Glucose -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Fasting Glucose -- (Safety Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Insulin Resistance (HOMA-IR) -- Homeostasis Model Assessment -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Insulin Resistance (HOMA-IR) -- Homeostasis Model Assessment -- (Safety Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Insulin -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Insulin -- (Safety Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Angiotensinogen -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Antithrombin Activity (AT III) -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Activated Partial Thromboplastin Time (aPTT) Based Activated Protein-C Resistance (APCr) (APCR-V Ratio) -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Prothrombin Fragment 1 + 2 -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Factor VIII -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Endogenous Thrombin Potential (ETP)-Based Activated Protein-C Sensitivity Ratio (APCsr ETP) -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Protein-C -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Free Protein-S -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Sex Hormone Binding Globulin (SHBG) -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Calcium -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • C-Terminal Telopeptide Type 1 (CTX-1) -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Procollagen I N-Terminal Propeptide (PINP) -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • 25-Hydroxyvitamin D -- (Efficacy Study Part)(Day 1 (Baseline), Weeks 12 and 52.)
  • Health-related Quality of Life (HRQoL) Assessment, Change From Baseline -- Menopause-specific Quality of Life (MENQOL) Questionnaire -- (Efficacy Study Part)(Day 1 (Baseline), Week 12, and 52.)
  • Health-related Quality of Life (HRQoL) Assessment, Change From Baseline -- Menopause-specific Quality of Life (MENQOL) Questionnaire -- (Safety Study Part)(Day 1 (Baseline), Week 12 and 52.)
  • Total Score in Treatment Satisfaction (TS) Using the Clinical Global Impression (CGI) Questionnaire -- (Efficacy Study Part, Safety Study Part)(Weeks 4, 12, and 52.)
  • Change From Baseline in Mean Endometrial Thickness -- (Efficacy Study Part, Safety Study Part)(Screening, Week 13, 29, 41, 53, Follow-up (Week 55/56), and early discontinuation (up to Week 53 for hysterectomized subjects and Week 55/56 for non-hysterectomized subjects))
  • Number of Subjects in the Different Endometrial Categories -- (Efficacy Study Part, Safety Study Part)(Screening and Week 53.)
  • Vaginal Bleeding and/or Spotting During Each 28-day Cycle of Treatment With E4 -- (Efficacy Study Part, Safety Study Part)(Cycle 1,2,3,4,5,6,7,8,9,10,11,12,13)
  • Number of Days With Bleeding or Spotting by Cycle for Non-Hysterectomized Subjects (Efficacy Study Part, Safety Study Part)(Cycle 1,2,3,4,5,6,7,8,9,10,11,12,13.)
  • Cumulative Rate of Amenorrhea (Absence of Any Bleeding or Spotting) During Each 28-day Cycle of Treatment With E4 -- (Efficacy Study Part, Safety Study Part)(Cycle 1,2,3,4,5,6,7,8,9,10,11,12,13.)
  • Number of Participants With Serious Adverse Events (SAE) in SOC 'Reproductive System and Breast Disorders' or With PT 'Abdominal Pain' by Hysterectomy Status (Hysterectomized and Non-Hysterectomized) -- (Efficacy Study Part, Safety Study Part)(Day 1 (allocation to treatment) until Week 53 (hysterectomized participants) or Week 55/56 (non-hysterectomized participants).)
  • Number of Participants With Non-serious Adverse Events (AEs) in SOC 'Reproductive System and Breast Disorders' or With PT 'Abdominal Pain' by Hysterectomy Status -- (Efficacy Study Part, Safety Study Part)(Day 1 (allocation to treatment) until Week 53 (hysterectomized participants) or Week 55/56 (non-hysterectomized participants).)

研究者

发起方
Estetra
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
2 期
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.Non-alcoholic Fatty Liver Disease (NAFLD)Non-alcoholic Steatohepatitis (NASH)
NCT04019561MedImmune LLC74
已完成
2 期
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaChronic Spontaneous Urticaria
NCT05368285Celldex Therapeutics208
已完成
2 期
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.InflammationCardiovascular RiskChronic Kidney Disease
NCT04626505Novo Nordisk A/S36
已完成
2 期
Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight SubjectsOverweightObesity
NCT00785408AstraZeneca273
已完成
2 期
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.Type 2 Diabetes Mellitus
NCT03244800MedImmune LLC65